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ABSTRACT 
 
Objectives: To assess the impact of both the Committee on Safety of Medicines (CSM) 
warning (December 2003) and the National Institute for Health and Care Excellence (NICE) 
guidance (September 2005) on anti-depressant prescription rates in children and 
adolescents within the UK primary care service.  
Setting: Population based study of primary care antidepressant prescribing using the 
Clinical Practice Research Datalink (CPRD). 
Participants: Under-18s presenting to primary care with a depressive disorder or related 
diagnostic code recorded in the CPRD. 
Primary outcome measure: Antidepressant prescription rates per month per 100,000 
depressed 4-17 year olds. 
Results: Following the CSM warning, the prior trend towards increased prescribing rates for 
Selective Serotonin Reuptake Inhibitors (SSRIs) in children was significantly reversed (β for 
change in trend -12.34 (95% CI -18.67 to -6.00, p <0.001)). However, after the publication of 
the NICE guidelines the prior trend towards increased prescribing resumed for those SSRIs 
mentioned as potential treatments in the guidance (fluoxetine, citalopram and sertraline) (β 
for change in trend 11.52 (95% CI 5.32 to 17.73, p <0.001)). Prescribing of other SSRIs and 
tricyclics remained low. 
Conclusions: Despite a strong emphasis on psychosocial interventions for child and 
adolescent depression, it may be that NICE guidelines inadvertently encouraged further anti-
depressant prescribing, at least for those SSRIs cited. Although the guidelines gave cautions 
and caveats for the use of antidepressants, practitioners may have interpreted these 
recommendations as endorsing their use in young people with depression and related 
conditions. However, more accurate prevalence trend estimates for depression in this age 
group, and information on the use of psychosocial interventions would be needed to rule out 
other reasons underlying this increase in prescribing.    
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Strengths and limitations of this study 
 The study uses a large and representative national dataset.  
 Analysing the data using an interrupted time series regression enabled estimation of 
the effect of two policy changes on the treatment of depression in young people in 
primary care. 
 Imprecise diagnostic coding in the dataset meant we had to take a broad definition of 
‘depression’ and related conditions. 
 We could only observe prescriptions issued by primary care. 
 For this study, we only had data up to 2010. 
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INTRODUCTION 
 
Depression is a common illness affecting approximately 3-6% of children and adolescents 
(1) and associated with impaired social and academic functioning (2, 3) and increased 
suicide risk (4). However, most depressed adolescents do not receive (specialist) treatment 
or support (5, 6). Within primary care settings practitioners are increasingly expected to 
detect child and adolescent depression at the earliest possible stage since the severity of 
depressive symptoms appears to correlate with serious consequences and negative 
behaviours (7).  
 
In treating childhood depression (as well as other disorders), anti-depressants have been 
commonly prescribed (8). During the late 1990s and early 2000s, Selective Serotonin 
Reuptake Inhibitors (SSRIs) became the preferred treatment for depression in children and 
adolescents rather than Tricyclic Antidepressants (TCAs) (9). However in June 2003, after 
the reanalysis of published and unpublished data on the SSRI paroxetine, the UK Medicines 
and Healthcare Products Regulatory Agency (MHRA) advised against its use in the 
treatment of child and adolescent depression (10). The decision was based on the 
observation that the drug was neither efficacious nor safe, with an apparent increased risk 
for self-harm and suicide (11). Later, in December 2003, the Committee on Safety of 
Medicines (CSM) reviewed the safety of all antidepressants in under 18s and advised 
against the initiation of venlafaxine and all other SSRIs, except fluoxetine (12). These 
reviews were subsequently followed by a ‘black box’ warning from the US Food and Drug 
Administration (FDA) in 2004 (13) and guidelines issued by the UK National Institute for 
Health and Care Excellence (NICE)  in 2005 (14). The NICE guidelines were produced to 
address the treatment and management of depression in children and young people and 
stated that no antidepressant should be used for mild depression. Furthermore 
recommendations were made so that psychological therapy should be offered for at least 
three months as a first line treatment for moderate to severe depression. For patients with 
inadequate response, fluoxetine could be offered in addition to psychological therapy to 
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children aged 12 to 18; for children 5 to 11, fluoxetine could also be considered but with 
significant caution. In case of fluoxetine non-response or poor tolerability, further drug 
treatment with either sertraline or citalopram could be considered.  
 
Prior to these warnings there was a trend towards increased prescribing for child and 
adolescent depression. Using data from the UK General Practice Research Database 
(GPRD- now renamed the Clinical Research Practice Datalink [CPRD]) to study the 
prevalence of overall antidepressant prescribing from 1992 to 2001, Murray and colleagues 
(8) found a 1.7 fold increase in prescriptions. In this period, the prevalence of tricyclic 
antidepressant prescriptions decreased by 30% (from 3.6 per 1000 in 1992 to 2.5 per 1000 
in 2001) while SSRI use increased 10-fold from 0.5 to 4.6 per 1000 in the same time period. 
The diagnosis of depression in under 18s was associated with the use of SSRIs in 69% of 
cases. A nationally representative US-based survey reported antidepressant medication use 
increased from 0.3 (1987) to 1.0 (1996) per 100 children and adolescents (15).  
 
Several studies investigating changes in prescribing trends have been published since the 
issue of US and UK warnings. Using the Disease Analyzer-Mediplus database, Murray and 
colleagues (16) concluded that fewer children and adolescents were prescribed 
antidepressants in primary care (6.6 per 1000 in 2000 to 5.7 in 2004). More specifically the 
prevalence of CSM-contraindicated antidepressant prescriptions declined by a third (from 
3.1 to 2.0 per 1000) whilst the prevalence of fluoxetine and non-SSRI antidepressants did 
not increase despite the guidance not mentioning these. The study suggests that CSM 
advice had a significant effect in reversing the rising prevalence of antidepressant 
prescribing. These findings were later replicated by Wijlaars et al (17) who demonstrated a 
significant drop in the rate of depression diagnoses and SSRI prescriptions around the time 
of the CSM announcement in 2003. However, rates for all anti-depressants (except 
paroxetine and imipramine) began to rise post 2005. Studies in Netherlands (18), USA (19), 
Australia (20) and five Western countries (21) have also shown that in general these 
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warnings were associated with (at least temporary) reductions in the prescribing of anti-
depressants, especially SSRIs.  In addition, Bergen and colleagues indicated that UK 
prescriptions of SSRIs decreased by 51% following the MHRA warning (22). More recently, 
overall antidepressant prescribing in children and adolescents has been shown have 
increased in Wales (23) and the wider UK (24).  
 
The aim of the present study was to analyse antidepressant prescribing trends, in relation to 
both the CSM warning and publication of NICE guidelines, for children and adolescents 
presenting to UK primary care services with depression between January 2000 and June 
2010 using data from the CPRD. Our hypotheses, based upon previous research, were that 
rates of prescribing both NICE ‘approved’ and ‘non-NICE’ SSRIs (that is those unmentioned 
for possible use by the guidelines) would decrease following both the CSM warning being 
issued and the publication of NICE guidelines in 2005, since these guidelines recommended 
first line use of psychological therapies where possible. In particular we expected a marked 
decrease in the prescription rates for antidepressants highlighted by both the CSM and NICE 
as those for which the potential benefits were likely to be outweighed by the risks.    
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METHODS 
For the purposes of the study three drug groups were investigated: (i) Medications named in 
the NICE Guidance CG28 as suitable for use in young people under the age of 18 with 
depressive illness (fluoxetine, citalopram and sertraline); (ii) all other non-NICE approved 
SSRIs (paroxetine, fluvoxamine, escitalopram); and (iii) tricyclic antidepressants 
(amitriptyline, clomipramine, doxepin, imipramine, nortrityline, trimipramine, dosulepin, 
lofepramine).   
 
Rates of primary care issued prescriptions for all medications listed under section 4.3 of the 
British National Formulary (25) as indicated for depressive illness were investigated. Within 
the UK approximately 98% of the population are registered with a general practitioner (26). 
We used information from the CPRD, which is maintained by the MHRA. The CPRD 
contains anonymised primary care records for approximately 5.5% of the UK population with 
data obtained from over 460 primary care practices, providing a total of 40 million patient 
years of clinical data (27). 
 
Prescription Rates 
Data were abstracted from the CPRD from GP practices where data were classified as ‘up-
to-standard’ (UTS) for at least 12 months during the study period of January 1st 2000 to June 
30th 2010. Only data where a patient had a relevant diagnostic code were included (see 
below). Prescribing rates for the three groups of antidepressants were generated by dividing 
the absolute number of depressed children who had a prescription issued (the numerator) by 
the number of under 18s with depression, as defined by the study (see below) within the 
dataset. This fraction was then multiplied by 100 000. Thus, the monthly rate reflected the 
mean number of prescriptions issued per 100 000 affected population. Prescription rates 
were calculated at the individual patient level; with repeat prescriptions and instances of re-
prescribing subsequently removed.  
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Depression and related conditions 
Cases were identified as any patient who was recorded as having received a first diagnosis 
of depression before the age of 17 within the study timeframe. Individuals were excluded 
from the study if CPRD data were not available for a period of 12 months following their 17th 
birthday. This approach was taken in order to reduce the risk of underestimating prescribing 
rates; if a young person of this age had a depression-related code they may well have had 
an antidepressant prescribed in the following 12 months.  
 
The operational definition of ‘depression’ was constructed by consensus within the research 
team using CPRD diagnostic (Read/OXMIS) codes. Depression is challenging to identify and 
diagnose in children and adolescents presenting in a primary care setting (28, 29). In an 
attempt to capture the maximum number of ‘true cases’ a wide range of CPRD diagnostic 
codes related to low mood, depressive illness and self-harm were included. See the 
supplementary file for the full list of the CPRD diagnostic codes utilised for this study. 
Diagnoses were carried forward for each time window so that diagnostic codes were not 
entered on multiple occasions.  
 
Statistical Analysis 
Prescription rates (number of prescriptions per 100 000 affected population) for 4-17 year 
olds were calculated for each month in the study period for each drug group from the CPRD 
data. The denominator was the number of young people in the CPRD data, per month, with 
a diagnosis of depression or related diagnostic code.  
 
Segmented linear regression analyses were performed. The magnitude of the slopes 
observed were formally tested in order to assess whether they significantly departed from 
zero. Our segmented regression followed the method described by Wagner et al.(30). All 
analyses were conducted with STATA version 14 (31). 
Ethics  
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The data were accessed within limits set out by the Medical Research Council licence 
agreement for academic access with Medical Research Ethics Committee ethical approval. 
The proposal was approved by the Independent Scientific Advisory Committee of the GPRD 
(protocol number 09_075R). In addition the study was exempt from external ethical approval 
on the basis that the data used for this study were de-identifiable and routinely collected. 
This was confirmed in writing by the chair of the Durham University School of Medicine, 
Pharmacy and Health’s Ethics Committee.  
 
RESULTS 
 
Overall the monthly prescription rates observed were very low, the highest observed value 
being for the NICE-recommended SSRIs in early 2010 at 762 prescriptions per 100,000 
affected 4-18 year olds. The possible reasons for these low observed prescribing rates are 
outlined in the discussion section. 
 
Interpretation of model parameters 
Segmented regressions with two ‘interruptions’ were performed, analysing changes in trend 
as a result of the CSM warning in December 2003 and the publication of the NICE guidance 
in September 2005. The base level parameter (β0) gives the rate of prescribing at the start of 
the data set. The base trend (β1) indicates how prescribing patterns were changing prior to 
the first interruption event i.e. issuing of the CSM. A positive coefficient indicates an increase 
in prescribing rate. The post CSM change in level (β2) gives the altered monthly prescribing 
rate following this warning. The post CSM interruption change in trend is denoted by the 
coefficient β3. The post-NICE change in level (β4) indicates the altered monthly prescribing 
rate following the publication of the NICE guidance. The change in trend following this 
second interruption is denoted by β5.       
 
Prescribing  
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Impact of CSM warning 
The full results are depicted in Table 1 and can also be visualised in Figure 1. Prescription 
rates of NICE cited SSRIs significantly increased in the years leading up to the CSM warning 
(β1= 5.24, 95% CI 3.43 to 7.05, p<0.001). This corresponds to a predicted prescription rate 
per month per 100,000 depressed 4-18 year olds (ppm) of 233 in January 2000, increasing 
to 474 ppm just before the CSM warning. In contrast ‘non-NICE’ SSRIs and tricyclic 
prescription trends were low and stable during this period. Following the issuing of the CSM 
warning only the prescribing trends for NICE cited SSRIs appeared to change, with a 
reduced rate (β3= -12.34, 95% CI -18.67 to -6.00, p<0.001).  
 
Impact of NICE Guidelines publication 
As can be seen from Table 1 and Figure 1, following release of the NICE Guidelines, there 
was a trend for an increase in the prescribing rate for NICE cited SSRIs (β3=11.52, 95% CI 
5.32 to 17.73, p<0.001). This equates to a modelled rise from 229 ppm at publication of the 
NICE guidance to 531 ppm at the end of the dataset. As can be seen from Table 1, all three 
NICE cited SSRIs contributed to this trend, with significant increases in their prescribing 
rates. Non-NICE and tricyclic antidepressant prescribing rates appeared unaffected and 
consistently relatively low.  
 
[Insert Table 1 here] 
 
 
[Insert Figure 1 here] 
DISCUSSION  
This is, to our knowledge, the first study evaluating the impact of both the CSM warning and 
NICE guidance on antidepressant prescribing trends in young people. The findings of this 
study contradict our hypothesis that the publication of NICE guidelines would result in a 
decrease in both NICE cited and non-cited SSRIs prescription rates. Rather, we observed a 
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trend towards increased prescription rates. More specifically, prior to the CSM warning there 
was a trend towards increased SSRI prescribing, at least for those medications destined to 
be cited by NICE as possible treatments for under 18s. Following the warning this trend was 
reversed, but appears to have resumed following publication of the NICE Guidelines. Our 
findings, at least in relation to the CSM warning, are in line with previous reports, highlighting 
a temporary reduction in prescription rates for antidepressants for under 18s following such 
official cautions (16-22).  
 
One interpretation of these findings is that despite a strong emphasis in the NICE guidelines 
upon utilising psychosocial interventions for child and adolescent depression, it may be that 
this publication inadvertently encouraged further anti-depressant prescribing. Although the 
guidelines gave cautions and caveats to their use, practitioners may have interpreted these 
recommendations as approval and validation for their widespread use. This ‘approval’ 
interpretation may also have been adopted by patients and their carers’ willingness to be 
prescribed these medications. Another factor underlying these trends may have been an 
increased pressure for primary care-based clinicians to prescribe SSRIs for young people 
affected by depression, anxiety or other mental health indications for the medications, such 
as Obsessive Compulsive Disorder (OCD). This could have occurred due to challenges with 
accessing secondary care located with Child and Adolescent Mental Health Services 
(CAMHS), for example, with the presence of increasingly long waiting lists during that period.  
Certainly, there are indications from ‘CAMHS Benchmarking’ reports that waiting lists for 
such secondary care services have increased over time and that, roughly, half of all referrals 
were not accepted by such teams (32).  It also may have been that young people were 
presenting with more severe depressive or anxiety symptoms, adding to the pressure to 
prescribe promptly in primary care. It is well established that depression, whilst relatively 
common in adolescents, often presents to primary care under the guise of physical medical 
complaints (33). An increased awareness, and changing attitudes towards mental health 
issues in the UK population may also have led to a higher proportion of affected young 
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people labelling their difficulties as being primarily psychological in nature, and thus receive 
a primary care antidepressant prescription (34).  
 
Strengths and limitations 
The study uses a large and representative dataset to estimate the effect of policy changes 
on the treatment of depression in young people in primary care. Our method of using an 
interrupted time series regression has also been adopted and highlighted as a strength by 
others analysing prescribing trends (22). This study builds on previous research into 
antidepressant prescribing rates in under 18s (8, 16, 21-24) by classifying SSRIs into those 
mentioned in the NICE guidance and those not cited. Additionally, by modelling an 
interruption at the time of the release of the guidance, we have been able to show trends 
which are consistent with the guidance inadvertently increasing the prescribing rates of 
citalopram and sertraline in particular. This study thus highlights the potential for clinical 
guidelines to have unintended consequences.  
 
The main limitation to our study was that we observed that absolute monthly prescription 
rates were lower than might be anticipated from previous, unrelated studies. This raises 
issues with the precision of either prescribing information and/or diagnostic problem category 
coding in our CPRD extract. However, in order to mitigate against imprecise diagnostic 
coding we took a broad definition of ‘depression’ and related conditions, including acts of 
self-harm. Nevertheless, we cannot exclude the possibility that some cases were missed. 
However, assuming the ‘measurement error’ was uniform and identically distributed 
throughout the study period the trends we elicited should remain valid, even if absolute 
prescribing rates themselves were systematically underestimated. It should also be noted 
that only monthly crude prescription rates were used in the trend analysis. Therefore, the 
influence of the same individual being switched from one antidepressant to another would 
not have been captured. However, these effects would have been subtle and likely to have 
been swamped by other sources of noise in the data, such as reporting accuracy.     
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It is likely that most psychotropic prescribing occurs in secondary care. Thus, our findings 
may not generalise to CAMHS prescribers. Moreover, it was not possible to discriminate 
between prescriptions initiated within primary care, and those taken over by practitioners 
within general practice, under the supervision, or at the request of CAMHS prescribers. From 
the data used it was also not possible to estimate the role of possible confounders in such 
trends, such as access to psychological therapies within the NHS (in spite of the NICE 
recommendations) and possible selection bias of compliance with NICE guidance among 
CPRD registered practices. It should also be noted that some of the tricyclic antidepressants 
have indications other than mental health problems such as enuresis (wetting) and 
neuropathic pain, and may have been prescribed for these reasons.  
 
Research and clinical implications 
In due course it would be important to analyse data post 2010 to see if the upward trend in 
approved SSRI prescriptions has continued and whether this increase is associated with 
improved clinical outcomes and suicide rates. It would also be useful to complement this 
analysis with referral rates over time for psychological therapies. Qualitative research might 
provide a rich narrative of how the guidance was received and interpreted and views about 
the balance of psychotherapeutic and drug intervention.  
 
In terms of clinical implications, previous studies have found evidence that the publication of 
warnings have been associated with significant reductions in aggregated rates of diagnosis 
and treatment of paediatric depression (35). However there may be limitations in continuing 
to extrapolate the CPRD dataset backward or forward in time due to changes in GP coding, 
CPRD diagnostic criteria and other contemporaneous clinical and policy influences.    
 
Finally, NICE specifically recommends varying the approach to treatment according to the 
severity of depression. Further more in-depth analysis might consider whether the 
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publication of NICE guidance influenced prescription rates according to depression severity 
(mild, moderate or severe) and whether certain medications were preferred depending upon 
severity. Unfortunately sub-categorisation of child and adolescent depression is not possible 
using the CPRD diagnostic codes. We also note that, whilst the changes to the original NICE 
guidelines were minimal, in relation to the update conducted in 2017, additional footnotes 
emphasised that fluoxetine was only licensed for the treatment of adolescents with 
depression if a previous trial of a psychological therapy had been unsuccessful. Moreover, 
the absence of specific licences for both sertraline and citalopram for the treatment of those 
under 18 was stressed (36).  
 
Conclusion  
Prescription of NICE cited antidepressants in the UK increased significantly between 2005 
and 2010, following the publication of guidance for children and adolescents with 
depression, following an initial decrease after the CSM was issued. The rate of non-NICE 
recommended SSRIs and tricyclics prescriptions before and after publication remained low. 
Despite the guidelines strongly emphasising the role of psychosocial interventions for child 
and adolescent depression, it may be that the release of the NICE publication inadvertently 
encouraged higher rates of anti-depressant prescribing, and in particular that of sertraline 
and citalopram. Thus, practitioners possibly interpreted these cautious recommendations as 
endorsements for their use with young people presenting with distressing psychological 
symptoms.  
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Figure legend 
Figure 1: Prescribing rates for NICE cited SSRIs and non-NICE cited SSRIs. Also shown are 
the intercepts (vertical lines) and slopes for the associated segmented regression analyses, 
(NICE: National Institute for Health and Care Excellence).  
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Table 1: Results from segmented regression analyses of rate or prescribing in the UK in 4-18 year olds. (CI: confidence interval, NICE: 
National Institute for Health and Care Excellence) 
 
 
 
 
 
 
 Base level ( β0)  
(95% CI) 
p Base trend  
(β1) 
(95% CI) 
p Post-CSM 
intervention  
(β2) 
(95% CI) 
p Post-CSM 
change in trend  
(β3) 
(95% CI) 
p Post-NICE 
intervention  (β4) 
(95% CI) 
p Post-NICE 
change in 
trend  (β5) 
(95% CI) 
p 
NICE cited 
SSRIs 
232.70 
(184.33, 281.07) 
<0.001 5.24 
(3.43, 7.05) 
<0.001 -107.94 
(-194.72, -21.15) 
0.02 -12.34 
(-18.67, -6.00) 
<0.001 52.72 
(-34.95, 140.40) 
0.24 11.52 
(5.32, 17.73) 
<0.001 
Fluoxetine 144.26 
(112.62, 175.90) 
<0.001 2.10 
(0.92, 3.29) 
0.001 58.71 
(1.94, 115.78) 
0.04 -8.69 
(-12.83, -4.54) 
<0.001 60.06 
(2.71, 117.41) 
0.04 7.97 
(3.91, 12.03) 
<0.001 
Citalopram 75.61 
(47.99, 103.22) 
<0.001 2.89 
(1.85, 3.92) 
<0.001 -84.94 
(-134.49, -35.40) 
0.001 -4.65 
(-8.27, -1.03) 
0.01 44.40 
(-5.56, 94.35) 
0.08 5.52 
(1.98, 9.06) 
0.002 
Sertraline 13.31 
(0.39, 4.62) 
0.12 2.30 
(1.67, 2.93) 
<0.001 -62.57 
(-92.24, -32.90) 
<0.001 -62.57 
(-92.24, -32.90) 
<0.001 -16.02 
(-45.84, 13.80)  
0.29 2.51 
(0.39, 4.62) 
0.02 
Non-NICE 
SSRIs 
116.40 
(100.89, 131.91) 
<0.001 -0.25 
(-0.83, 0.34) 
0.41 -37.78 
(-65.61, -9.95) 
0.01 -0.16 
(-2.19, 1.88) 
0.88 -21.12 
(-49.24, 7.00) 
0.14 0.61 
(-1.38, 2.60) 
0.54 
Tricyclics 78.65 
(59.44 to 97.85) 
<0.001 0.55 
(-0.17, 1.27) 
0.14 -0.96 
(-35.41 to 33.49) 
0.96 -1.68 
(-4.20, 0.84) 
0.19 -4.73 
(-39.54, 30.08) 
0.79 1.89 
(-0.58, 4.35) 
0.13 
